Structural characterization of pharmaceutical heparins prepared from different animal tissues

Journal of Pharmaceutical Sciences

Volumn 102, Issue 5, 2013, Pages 1447-1457

  Fu, Li ^a,b   Li, Guoyun ^b,c   Yang, Bo ^b   Onishi, Akihiro ^b,d   Li, Lingyun ^b   Sun, Peilong ^a   Zhang, Fuming ^b   Linhardt, Robert J ^b,d  

^a ZHEJIANG UNIVERSITY OF TECHNOLOGY   (China)

^b RENSSELAER POLYTECHNIC INSTITUTE   (United States)

^c OCEAN UNIVERSITY OF CHINA   (China)

^d RENSSELAER POLYTECHNIC INSTITUTE   (United States)

Author keywords

Antithrombin III; Bioanalysis; Glycosaminoglycans; Heparin; LC MS; Mass spectomery; surface plasmon resonance; NMR

Indexed keywords

ANTITHROMBIN III; DISACCHARIDE; HEPARIN; MONOSACCHARIDE; TETRASACCHARIDE;

ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CARBOHYDRATE ANALYSIS; CARBON NUCLEAR MAGNETIC RESONANCE; COW; DRUG STRUCTURE; HYDROPHILICITY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MEASUREMENT; MOLECULAR WEIGHT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHYSICAL CHEMISTRY; PROTON NUCLEAR MAGNETIC RESONANCE; STRUCTURE ANALYSIS; SURFACE PLASMON RESONANCE; SWINE;

EID: 84876335231     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23501     Document Type: Article

References (19)

1. Linhardt RJ. 2003. Heparin: Structure and activity. J Med Chem 46:2551-2554.
2. Lindahl U, Backstrom G, Thunberg L, Leder IG. 1980. Evidence for a 3-O-sulfated d-glucosamine residue inthe antithrombin-binding sequence of heparin. Proc Natl Acad Sci USA 77:6551-6555.
3. Loganathan D, Wang HM, Mallis LM, Linhardt RJ. 1990. Structural variation in the antithrombin III binding site region and its occurrence in heparin from different sources. Biochemistry 29:4362-4368.
4. Linhardt RJ, Ampofo SA, Fareed J, Hoppensteadt D, Mulliken JB, Folkman J. 2005. Isolation and characterization of human heparin. Biochemistry 31:12441-12445.
5. Hovingh P, Piepkorn M, Linker A. 1986. Biological implications of the structural, antithrombin affinity and anticoagulant activity relationships among vertebrate heparins and heparan sulphates. Biochem J 237:573-581.
6. Luppi E, Cesaretti M, Volpi N. 2005. Purification and characterization of heparin from the Italian clam Callista chione. Biomacromolecules 6:1672-1678.
7. Schonberger LB. 1998. New variant Creuzfeldt-Jakob disease and bovine spongiform encephalopathy. Infect Dis Clin North Am 12:111-121.
8. Liu H, Zhang Z, Linhardt RJ. 2009. Lessons learned from the contamination of heparin. Nat Product Rep 26:313-321.
9. Guerrini M, Beccati D, Shriver Z, Naggi AM, Bisio A, Capila I, Lansing J, Guglieri S, Fraser B, Al-Hakim A, Gunay S, Viswanathan K, Zhang Z, Robinson L, Venkataraman G, Buhse L, Nasr M, Woodcock J, Langer R, Linhardt RJ, Casu B, Torri G, Sasisekharan R. 2008. Oversulfated chondroitin sulfateis a major contaminant in heparin associated with adverse clinical events. Nat Biotechnol 26:669-775.
10. Kishimoto TK, Viswanathan K, Ganguly T, Elankumaran S, Smith S, Pelzer K, Lansing JC, Sriranganathan N, Zhao G, Galcheva-Gargova Z, Al-Hakim A, Bailey GS, Fraser B, Roy S, Rogers-Cotrone T, Buhse L, Whary M, Fox J, Nasr M, Dal Pan GJ, Shriver Z, Langer RS, Venkataraman G, Austen KF, Woodcock J, Sasisekharan R. 2008. Contaminated heparinassociated with adverse clinical events and activation of the contact system. N Engl J Med 358:2457-2467.
11. Chen J, Jones CL, Liu J. 2007. Using an enzymatic combinatorial approach to identify anticoagulant heparansulfate structures. Chem Biol 14:986-993.
12. Guo X, Condra M, Kimura K, Berth G, Dautzenberg H, Dubin PL. 2003. Determination of molecular weight of heparin by size exclusion chromatography with universal calibration. Anal Biochem 312:33-39.
13. Guerrini M, Zhang Z, Shriver Z, Naggi A, Masuko S, Langer R, Casu B, Linhardt RJ, Torri G, Sasisekharan R. 2009. Orthogonal analytical approaches to detect potential contaminants in heparin. Proc Nat Acad Sci USA 106:16956-16961.
14. Zhang F, Yang B, Ly M, Solakyildirim K, Xiao Z, Wang Z, Beaudet JM, Torelli AY, Dordick JS, Linhardt RJ. 2011. Structural characterization of heparins from different commercial sources. Anal Bioanal Chem 401:2793-2803.
15. Linhardt RJ, Rice KG, Kim YS, Lohse DL, Wang HM, Loganathan D. 1988. Mapping and quantification of the major oligosaccharide components of heparin. Biochem J 254:781-787.
16. Zhang Z, Xie J, Liu H, Liu J, Linhardt RJ. 2009. Quantitification of heparan sulfate and heparin disaccharides using ion pairing, reverse-phase, micro-flow, high performance liquid chromatography coupled with electrospray ionization trap mass spectrometry. Anal Chem 81:4349-4355.
17. Xiao Z, Tappen BR, Ly M, Zhao W, Canova LP, Guan H, Linhardt RJ. 2011. Heparin mapping using heparin lyases and the generation of a novel low molecular weight heparin. Med Chem 54:603-610.
18. Li L, Zhang F, Zaia J, Linhardt RJ. 2012. Top-down approach for the direct characterization of low molecular weight heparins using LC-FT-MS. Anal Chem 84:8822-8829.
19. Beaudet JM, Weyers A, Solakyildirim K, Yang B, Takieddin M, Mousa S, Zhang F, Linhardt RJ. 2011. Affect of autoclave sterilization on the activity and structure of formulated heparin. J Pharm Sci 100:3396-3404.